恩考拉非尼联合比美替尼的药物相互作用潜力评价:Inje鸡尾酒法
在BRAF V600突变晚期实体瘤患者中,采用Inje鸡尾酒法评估恩考拉非尼单次和多次给药对CYP2C9、CYP3A4、CYP1A2、CYP2C19和CYP2D6探针底物药代动力学的影响。结果显示恩考拉非尼稳态时是CYP3A的强诱导剂,使咪达唑仑Cmax和AUClast分别降低74%和82%,对其他探针底物无临床显著相互作用。
要点
- 恩考拉非尼稳态时是CYP3A强诱导剂,咪达唑仑AUC降低≥80%。
- 与恩考拉非尼联用时,应避免或根据说明书调整CYP3A敏感底物剂量。
- 恩考拉非尼对其他CYP探针底物无临床显著相互作用。
核心结论
- 恩考拉非尼在稳态浓度下是CYP3A的强诱导剂,使咪达唑仑AUC降低≥80%。
- 基于此结果,与恩考拉非尼联用时,CYP3A敏感底物应避免使用或根据其批准说明书调整剂量。
研究设计与样本
- 在BRAF V600突变晚期实体瘤患者中开展的上市后药物相互作用临床研究。
- 患者在第-7天、第1天和第14天接受Inje鸡尾酒(含氯沙坦、咪达唑仑、咖啡因、奥美拉唑、右美沙芬),并从第1天起连续服用恩考拉非尼450 mg每日一次和比美替尼45 mg每日两次。
- 在鸡尾酒给药日进行0至8小时的PK采血和尿液收集,采用非房室分析计算PK参数。
主要发现
- 恩考拉非尼稳态血浆浓度下,咪达唑仑血浆Cmax和AUClast分别降低74%和82%。
- 恩考拉非尼稳态浓度下与其他感兴趣探针底物(氯沙坦、咖啡因、奥美拉唑、右美沙芬)未观察到临床显著DDI。
关键数值与推荐
- 恩考拉非尼稳态时是CYP3A强诱导剂(咪达唑仑AUC降低≥80%)。
- 与恩考拉非尼联用时,CYP3A敏感底物应避免或根据其批准说明书调整剂量。
临床怎么用
- 临床使用恩考拉非尼时,应审查合并用药,避免联用CYP3A敏感底物。
- 若必须联用CYP3A敏感底物,应根据其说明书调整剂量。
- 恩考拉非尼与CYP2C9、CYP1A2、CYP2C19、CYP2D6底物联用无需特别调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered as a cocktail (Inje). This study was conducted, post-approval, in patients with BRAF V600-mutant advanced solid tumors, and aimed to address the remaining uncertainty in the DDI potential of encorafenib as a perpetrator of these CYP enzymes. Study participants received the cocktail on Days -7, 1, and 14 and continuous doses of encorafenib (450 mg q.d.) and binimetinib (45 mg b.i.d.) starting on Day 1. PK sampling and urine collection were conducted from 0 to 8 hours on cocktail administration days. PK parameters were calculated for each participant using noncompartmental analysis of concentration-time data or amount excreted for urine parameters. At steady-state encorafenib plasma concentrations, midazolam plasma Cmax and AUClast decreased by 74% and 82%, respectively. No clinically significant DDIs were observed at encorafenib steady-state concentrations with the other probe substrates of interest. The results from this clinical study indicate that encorafenib is a strong inducer of CYP3A (≥ 80% decrease in midazolam area under the curve (AUC)) at steady state. Based on these results regarding co-administration with encorafenib, sensitive substrates of CYP3A should be avoided or dose adjusted based on the recommendations of their approved product labeling. This information has been included in the updated prescribing information for encorafenib.
引用
- Piscitelli J, Reddy MB, Wollenberg L, et al. An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer. Clin Pharmacol Ther. 2025. PMID: 41215578. doi:10.1002/cpt.70117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。